Event

25

September 2018

Growing the Life Sciences Industry: Improving Access, Affordability & Appropriate Use of Medicines - Can we have it all?

11:30am-1:30pm | Fairmont Chateau Laurier Hotel - 1 Rideau Street, Ottawa

Affordability of and access to innovative medicines are challenges that Canada shares with many other countries around the world. With healthcare budgets stretched due to rising drug prices and ageing populations with increasingly complex conditions, those challenges continue to increase. Addressing these issues requires creative policy and market-based approaches that draw on the best ideas around the world.

Join us as our expert panellists discuss different approaches from around the world in balancing affordability and access, while building a strong life sciences industry.

- Lunch will be served -

Member price:
Individual seat: $89 +HST
Table (seats 10): $800 +HST

Regular price:
Individual seat: $110 +HST
Table (seats 10): $990 +HST

Important:
- For information about accessibility, please email lapointe@economicclub.ca
- Dietary restriction notes and meal requests must be submitted to lapointe@economicclub.ca by Tuesday, September 18, 2018.

*The views expressed on the Economic Club platform are not that of the Economic Club or its affiliates but of the speakers alone and the organizations they represent*

Thank you to our Event Sponsors:

Growing the Life Sciences Industry: Improving Access, Affordability & Appropriate Use of Medicines - Can we have it all?

Brian Hilberdink

President
Novo Nordisk Canada Inc.

Brian Hilberdink

Brian Hilberdink is the President of Novo Nordisk Canada. His 22-year career includes several years at the company’s headquarters in Denmark in the Global Marketing organisation, in addition to a variety of roles with Novo Nordisk in the U.S. Brian is an active contributor on the Board of Innovative Medicines Canada and BIOTECanada, and is also a founding member of the Diabetes Canada Impact Council.

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given it experience and capabilities that also enable it to help people defeat obesity, hemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries, and markets its products in more than 170 countries.

Hans Erik Henriksen

CEO
Healthcare Denmark

Hans Erik Henriksen

In 2013, Hans Erik Henriksen became CEO of Healthcare DENMARK, a public-private non-profit partnership that has a national and political mandate to promote Danish healthcare excellence and visibility internationally. He has a strong international background within e-Health and he has previously headed a range of health sector activities at IBM. He has also been one of the driving forces behind the Danish clinical logistics company, Cetrea, which now holds a leading position in Denmark and has many international activities. At Healthcare Denmark, Hans Erik is working to raise awareness of the Danish healthcare system and its strongholds, internationally.

Ilse Treurnicht

Former CEO
MaRS Discovery District

Ilse Treurnicht

Dr. Ilse Treurnicht has been an entrepreneur and executive in a number of emerging technology companies. In 2005, she became CEO of MaRS, which is a non-profit corporation that works to foster better conditions for innovators and entrepreneurs by providing access to critical talent, capital, specialized infrastructure and customer networks. Now she is the Executive Chair of Triphase Accelerator Corporation.

Triphase Accelerator acquires promising cancer therapies and accelerates their development, leveraging their deep relationships with world-class scientists, clinicians and business professionals with access to state-of-the-art facilities and capabilities.

She was Chair of the Canadian Task Force on Social Finance in 2010, and serves on the Government of Canada’s Science, Technology and Innovation Council (STIC) and the Advisory Council on Economic Growth.

Ilse holds a M.Sc. in Chemistry from Stellenbosch University, South Africa, and a D.Phil. in Chemistry from University of Oxford, United Kingdom.

Sheryl Groeneweg

Director General, Manufacturing & Life Sciences Branch
Innovation, Sciences and Economic Development Canada

Sheryl Groeneweg

Sheryl Groeneweg is the Director General for the Manufacturing and Life Sciences Branch at Innovation, Sciences and Economic Development Canada (ISED), where she oversees policy development aimed at retaining and growing innovative manufacturing sectors critical to the Canadian economy, including advanced manufacturing, life sciences, food processing, services to manufacturing, steel, chemicals, artificial intelligence and emerging technologies.

In her tenure in the Public Service of Canada, Sheryl has held positions at the Privy Council Office, Natural Resources Canada, Transport and Infrastructure Canada, Indian and Northern Affairs and Human Resources Development Canada.

Sheryl holds a Master of Arts and Bachelor of Arts in English Literature and a Bachelor of Arts Degree in Economics from Carleton University.

Our Sponsors